Results

Rhythm Pharmaceuticals Inc.

10/14/2021 | Press release | Distributed by Public on 10/14/2021 14:04

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes